Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRB2 | P47870 | 4/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.44 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28391511 | 0.88 | GABRA2 (0.48) | GABRB2HDAC1GABRA2 | |
| SCHEMBL7241456 | 0.88 | GABRA1 (0.49) | GABRB2GABRA1GABRA2 | |
| SCHEMBL7554629 | 0.88 | KCNK3 (0.47) | GABRB2KCNK3KCNK9PTGDR2GABRA2 | |
| SCHEMBL28395148 | 0.82 | GABRA1 (0.48) | GABRB2GABRA1HDAC1KCNK3KCNK9 | |
| SCHEMBL7233460 | 0.80 | SMN1; SMN2 (0.52) | — | |
| SCHEMBL8710565 | 0.77 | AKR1B1 (0.39) | — | |
| SCHEMBL8704447 | 0.77 | AKR1B1 (0.44) | PTGDR2 | |
| SCHEMBL1691336 | 0.76 | KDM4E (0.48) | GABRB2GABRA1KCNK3KCNK9SLC2A1 | |
| SCHEMBL7235014 | 0.75 | RAB9A (0.53) | GABRB2GABRA1GABRA2 | |
| SCHEMBL8208 | 0.75 | KDM4E (0.64) | GABRB2GABRA1KCNK3KCNK9SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020032200-A1 | 2-Substituted imidazo[1,2-A]pyridine derivatives | NEUROGEN CORPORATION | 2002-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032200-A1 | 2-Substituted imidazo[1,2-A]pyridine derivatives | GABBR2, GABRP, GABBR1 | GABRB2 6/4885GABRA1 5/4885HDAC1 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.